Increlex (mecasermin) — Medica
Growth Hormone Gene Deletion with neutralizing antibodies to growth hormone
Initial criteria
- Patient is ≥ 2 years of age
- The epiphyses are open
- Patient has developed neutralizing antibodies to growth hormone
- Patient will not be receiving concurrent treatment with growth hormone
- Medication is prescribed by or in consultation with a pediatric endocrinologist
Reauthorization criteria
- Patient’s height has increased by ≥ 2 cm/year in the most recent year
- The epiphyses are open
- Patient has developed neutralizing antibodies to growth hormone
- Patient will not be receiving concurrent treatment with growth hormone
Approval duration
1 year